Health
Popular vitamin D supplement may have an unexpected effect, experts warn
NEWYou can now listen to Fox News articles!
Vitamin D is known to be essential to many aspects of human health — but a new study suggests that taking a certain form of it can have a negative effect.
The more potent and longer-lasting form, vitamin D3 (cholecalciferol) is produced naturally when the body is exposed to sunlight and is also found in animal products, while vitamin D2 (ergocalciferol) comes from plant or fungal sources, per the National Institutes of Health.
Researchers from the University of Surrey in the U.K. found that taking vitamin D2 can cause reduced levels of vitamin D3 in the body.
OVERLOOKED SUPPLEMENT COULD SLOW AGING AND BOOST BRAIN AND HEART HEALTH, EXPERT SAYS
They made this determination by analyzing 11 randomized controlled trials including 655 adults, which showed that people taking vitamin D2 supplements had less vitamin D3 than those who did not take D2, according to a university press release.
The findings of the study — conducted along with the John Innes Centre and the Quadram Institute Bioscience in Norwich, England — were published in the journal Nutrition Reviews.
Vitamin D is known to be essential to human health — but a new study suggests that taking a certain form of it can have a negative effect. (iStock)
“Vitamin D supplements are important, especially between October and March, when our bodies cannot make vitamin D from sunlight in the U.K.,” lead researcher Emily Brown, a Ph.D. research fellow from the University of Surrey’s Nutrition, Exercise, Chronobiology & Sleep Discipline, stated in the press release.
“However, we discovered that vitamin D2 supplements can actually decrease levels of vitamin D3 in the body, which is a previously unknown effect of taking these supplements. This study suggests that, subject to personal considerations, vitamin D3 supplements may be more beneficial for most individuals over vitamin D2.”
COMMON VITAMIN SHOWN TO SLASH SKIN CANCER RISK IN SOME GROUPS, STUDY SUGGESTS
Previous research has suggested that the two forms of vitamin D are not interchangeable. A study published in Frontiers in Immunology, also conducted by the University of Surrey, found that vitamin D3 is more effective in boosting the immune system and protecting the body from viral and bacterial diseases, the release noted.
Some foods containing vitamin D3 include fatty fish, egg yolks, cod liver oil and fortified dairy and animal foods, health sources confirm. (iStock)
“We have shown that vitamin D3, but not vitamin D2, appears to stimulate the type I interferon signaling system in the body – a key part of the immune system that provides a first line of defense against bacteria and viruses,” stated Professor Colin Smith, who led the above study. “Thus, a healthy vitamin D3 status may help prevent viruses and bacteria from gaining a foothold in the body.”
Professor Martin Warren, chief scientific officer at the Quadram Institute, confirmed in the release that vitamin D deficiency is a “significant public health concern,” particularly during the winter months.
“This collaborative research effort aligns well with the Quadram Institute’s mission to deliver healthier lives through food innovation to enhance the nutrient density of the food we eat,” he said. “Tackling this with the most effective form of vitamin D supplementation or fortification is of the utmost importance to the health of the nation.”
More research is needed to determine whether vitamins D2 and D3 affect the body differently — and whether that could change doctors’ medical advice on which type to take, the researchers concluded. (iStock)
More research is needed to determine whether vitamins D2 and D3 affect the body differently — and whether that could change doctors’ medical advice on which type to take, the researchers concluded.
There were several limitations to the analysis, the study findings noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
For example, there were only a small number of studies with many differences among them, such as their duration, the amount and timing of doses, and how results were measured. There was also the potential for biases due to incomplete reporting of details.
The results could also be affected by factors such as the amount of sunlight exposure, as well as some people taking supplements and others eating vitamin-fortified foods, the researchers noted.
CLICK HERE FOR MORE HEALTH STORIES
Some foods containing vitamin D3 include fatty fish, egg yolks, cod liver oil and fortified dairy and animal foods, health sources confirm. Vitamin D2 can be found in mushrooms, fortified foods and some plant/fungal-based supplements.
The study was supported by the Biotechnology and Biological Sciences Research Council (BBSRC).
Health
Experimental obesity drug outperforms traditional weight-loss treatments in early research
NEWYou can now listen to Fox News articles!
A new weight-loss drug variation is showing promise in early trials.
Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani.
The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity, inflammation, fat metabolism and liver health.
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS
The team of researchers, led by Professor Timo D. Muller at Helmoltz Munich, called the drug a quintuple agonist, as it targets five receptor systems.
In a press release, Muller described the drug as a “Trojan horse”: the incretin component — hormones that help regulate blood sugar and appetite — allows it to enter target cells, and once inside, the PPAR “cargo” activates to help the body better use insulin, process fat and reduce inflammation.
The researchers hope the “Trojan horse” effect will allow for lower dosing and fewer side effects. (iStock)
This allows for the dosage of the drug to be lower, which could reduce side effects.
“A major advantage is the amount,” Muller said. “Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower.”
NEW WEIGHT-LOSS SHOT SHOWS MAJOR FAT REDUCTION, BUT EXPERTS URGE CAUTION
The study tested the drug combination in mouse models, including mice with diabetes-induced obesity, insulin resistance and genetic obesity.
In these mice, the compound was found to lower body weight, food intake, fat mass, blood sugar and insulin-related problems more than GLP-1 and GIP alone. It also outperformed semaglutide.
CLICK HERE FOR MORE HEALTH STORIES
The researchers reported that typical gastrointestinal side effects were similar to those seen with existing therapies.
“We see a principle with strong effects in the animal model — now the task is to optimize the approach for humans and move it toward the clinic,” Muller said in the release.
The preclinical study was conducted in mouse models and cannot yet be applied to humans. (iStock)
Dr. Peter Balazs, MD, a hormone and weight-loss specialist practicing in New York and New Jersey, said the drug is designed to target obesity and insulin resistance “at multiple key sites simultaneously, including the brain, pancreas and metabolic tissues.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“This is a novel mechanism because it’s not just relying on a higher dose of an existing drug,” he told Fox News Digital in an interview.
“Current GLP-1 medications are highly effective appetite suppressants, while this quintuple agonist seems to function both as an ‘appetite brake’ and a metabolic engine,” he added.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above” while also “directly improving insulin sensitivity in the liver and muscle, reducing inflammation in adipose tissue and remodeling lipid metabolism,” the expert confirmed.
While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above,” an expert said. (iStock)
“The result may be greater weight loss through a combination of caloric restriction, enhanced fat oxidation and potentially increased central energy expenditure,” Balazs said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Although the drug provides a “promising direction for the future,” Balazs noted that the study was conducted only on mouse models and there is no human safety or efficacy data, which means the drug cannot yet be recommended for clinical use.
“Additionally, it was conducted over a relatively short period of time, so we cannot draw conclusions about long-term effects,” he added.
Health
With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win
Over lunch at his golf club in Jupiter, Fla., on the first Saturday of May, President Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.
Eventually Mr. Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the F.D.A. commissioner.
No answer.
Furious, the president then dialed Dr. Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the F.D.A.’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.
The message was received. Less than one week later, the executives got what they wanted.
On Friday, the F.D.A. issued new guidance that could pave the way for major tobacco companies to begin selling flavored vapes and to snare a chunk of the $6 billion e-cigarette market away from illegal Chinese competitors. The new policy bypassed the F.D.A.’s regular rule-making process.
In the intervening week, Dr. Makary continued to argue against approving flavored vapes as support from Mr. Kennedy and others collapsed around him. Health and Human Services Department staff began to draft the new plan, according to two people familiar with the events.
On Tuesday, Dr. Makary resigned, telling associates he could not in good conscience remain the head of an agency that backed such a policy.
Though there is no definitive evidence linking the new guidance to donations or lobbying, the episode represented a clear pivot in the federal government’s longtime approach to the tobacco industry.
Since the 1990s, when states extracted vast payments and other concessions from the major cigarette companies in a nationwide legal settlement, Big Tobacco has been in retreat. Cigarette sales have plummeted, and regulations have mounted as consumers and administrations from both parties embraced public health consensus about the dangers of smoking and nicotine addiction.
Mr. Trump’s first administration initially continued the trend, proposing further restrictions on cigarettes and moving to outlaw flavored vapes over concerns that their rising popularity threatened the health of a generation of adolescents.
But since then, Mr. Trump has enthusiastically welcomed the financial support of the tobacco industry and has courted e-cigarette users as a political constituency.
The new vaping guidance highlights Mr. Trump’s willingness to use his executive authority to prioritize the causes of major corporate donors over public health concerns, taxpayer interests and the judgment of experts, sometimes including those in his own administration.
The president has developed a close relationship with tobacco companies including Altria and Reynolds American, which have donated millions of dollars to his political groups and projects, including his proposed White House ballroom. Their executives attended the lunch at the president’s golf club.
The Department of Health and Human Services, which oversees the F.D.A., referred requests for comment to the White House.
Kush Desai, a White House spokesman, said in a statement that Mr. Trump has pushed to expand access to vapes to help Americans trying to quit smoking.
“The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Mr. Desai said.
Reynolds American and Altria did not respond to questions about their lobbying or the conversation at the lunch.
It was attended by Jeff Raborn, a top executive at Reynolds, and Phil Park and Todd Walker of Altria, according to the people familiar with the meeting. Also attending were Brian Ballard and Rich Haselwood, lobbyists for the firm Ballard Partners, which represents Reynolds and helped marshal a sophisticated and expensive influence campaign that culminated in the new vaping guidance. Mr. Ballard is a top fund-raiser for Mr. Trump. Mr. Haselwood had been an in-house lobbyist at Reynolds before joining Ballard Partners this year.
A spokesman for Ballard Partners declined to comment.
While public health experts consider e-cigarettes a less harmful alternative to tobacco-burning cigarettes, the new guidance circumvents a scientific review process the F.D.A. had previously defended up to the Supreme Court. The disregarded procedures were meant to ensure approval of only those products shown in studies to help cigarette smokers transition to vapes without attracting a new generation of nicotine users.
The guidance also could allow higher nicotine levels in nicotine pouches. It includes a pledge to prioritize efforts to stop the import of illegal foreign vapes, an idea that has bipartisan support in Congress.
Taken together, the policy changes could help companies like Altria and Reynolds gain market share considered central to the survival of the industry.
The market for vapes and nicotine pouches, like Zyn, is about 30 million people in the United States, on par with the number of cigarette smokers. While the nicotine pouch market is rapidly growing, cigarettes still account for about $50.8 billion, or nearly 70 percent of the annual tobacco sales in the United States, according to a Goldman Sachs research report. Vape sales have lagged amid competition from illicit products.
In recent years, the F.D.A. has moved glacially to approve e-cigarettes, authorizing only those in tobacco or menthol flavors, including some sold by Reynolds and Altria. Unapproved Chinese vapes have poured into the United States, feeding a thriving illicit market with flavors like peach slush and watermelon ice. Last year, industry executives have said, illicit fruit-flavored vapes made up 60 percent of the e-cigarette market.
When Mr. Trump mounted his bid to return to the White House, some in the tobacco industry went all in, hoping he would loosen regulations on vapes and abandon plans by the Biden administration to ban menthol cigarettes and crack down on other cigarette sales.
Mr. Trump in some ways makes for an unlikely savior for the tobacco industry. He has never smoked, but he pledged during his 2024 campaign to “save vaping again.”
Through a subsidiary, Reynolds, which is the biggest seller of menthol cigarettes, donated $10 million to a super PAC backing Mr. Trump’s campaign, according to campaign finance filings. There is no public record of the subsidiary donating to groups supporting Mr. Biden or the campaign of former Vice President Kamala Harris.
Mr. Ballard, whose firm has been paid more than $4.4 million by Reynolds since the beginning of 2017, arranged for Mr. Trump to have dinner during the campaign with Reynolds executives in New York, according to a person familiar with the interactions. The executives urged Mr. Trump to oppose the menthol cigarette ban and expressed concern about Chinese vapes.
Reynolds executives including Mr. Raborn and Mr. Haselwood were such a presence around the campaign that Mr. Trump took to calling them “my tobacco guys,” according to the person familiar with the interactions and a book coauthored by a New York Times reporter and published last year.
When Mr. Trump won, the rest of the industry jockeyed to show support.
Altria donated $1 million to his inaugural committee; the Vapor Technology Association donated $1.25 million; and a subsidiary of Philip Morris donated $500,000.
On Mr. Trump’s second full day in office, his administration withdrew the proposed ban on menthol cigarettes, an initiative the Biden administration had already mostly abandoned. Mr. Trump’s team also set aside a Biden-era proposal to sharply restrict nicotine in cigarettes, an effort meant to speed the transition away from a product known to be deadly.
In applauding the withdrawal of the menthol ban, Billy Gifford, the chief executive of Altria, told investors on an April 2025 earnings call that “we’re hopeful that that activity and momentum continues.”
The courtship intensified.
Reynolds pitched in another $3 million to a different Trump-backed super PAC, while Altria and Juul each donated $1 million.
And Reynolds and Altria each donated to the effort to raise private funds to build a new White House ballroom. Mr. Raborn of Reynolds and Mr. Walker of Altria were invited to a dinner at the White House in October for donors who gave $2.5 million or more, as was Mr. Ballard.
Tadeu Marroco, the chief executive of British American Tobacco, which owns Reynolds American, predicted to investors earlier this year that the Trump administration would clamp down on illegal vapes, saying “it’s very encouraging, the signs that the new administration is giving to address that.”
The companies’ lobbying strategy also has reached into the states, where they are pushing for so-called “registry laws” — of which there are now more than a dozen including in Florida, Virginia and Pennsylvania. Many of those laws restrict e-cigarette sales to only vapes on a list from the F.D.A.
The guidance released last week said it would create such a list.
Sheryl Gay Stolberg contributed reporting.
Health
First clade I mpox case confirmed in Connecticut after patient traveled to Western Europe
NEWYou can now listen to Fox News articles!
A case of clade I mpox — a more virulent version of the virus that causes monkeypox, according to the Centers of Disease Control and Prevention (CDC) — has been confirmed in the U.S., as global health officials also monitor newly reported hantavirus cases in Europe.
The Connecticut Department of Public Health (CDPH) said Wednesday that the state’s first identified case of clade I mpox was detected in a person who recently traveled to Western Europe, where officials continue to monitor infectious disease activity.
The World Health Organization (WHO) has also reported new hantavirus cases in Spain and France, drawing attention to the rare but potentially severe disease, which can cause serious respiratory complications in humans.
Hantavirus is typically spread through contact with infected rodents and can lead to severe respiratory illness, though cases remain rare, according to the WHO.
While health officials said the mpox case “does not pose a risk to the general public,” they still encourage those who may be at risk to receive the JYNNEOS vaccine.
NEW MPOX STRAIN CONFIRMED IN US STATE FOR FIRST TIME
A pharmacist wearing a latex glove holds a photo of the mpox virus, which can spread through close, intimate contact with an infected person. (iStock)
Mpox symptoms can include fever, swollen lymph nodes and a characteristic rash, according to CDC.
“Mpox hasn’t gone away, and we want people to be protected, especially as many in our community prepare for travel, festivals, and gatherings this summer,” CDPH Commissioner Dr. Manisha Juthani said in the release.
“The vaccine is safe, effective and widely available. Completing the two-dose series is the best way to protect yourself and your partners.”
HANTAVIRUS DEATHS ON CRUISE SHIP HIGHLIGHT DANGERS OF RODENT-BORNE DISEASE
Clade I mpox, a newer strain of the virus, first appeared in California in November 2024. (iStock)
Clade I and clade II mpox are genetically distinct forms of the virus with key differences in severity and geographic origin, according to the CDC and the WHO.
Clade I, historically identified in Central Africa, has been linked to more severe illness and higher mortality rates, with cases often involving more widespread rashes and complications.
A traveler walks past a sign in a busy airport about mpox. (Yasuyoshi Chiba/AFP)
Clade II, which has circulated primarily in West Africa, is generally associated with milder disease and drove the global outbreak beginning in 2022, when most patients experienced less severe symptoms and lower hospitalization and death rates, according to the WHO.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The CDC and WHO say distinguishing between the two clades helps guide risk assessments, particularly as international travel increases.
-
Politics4 minutes agoJordan grills Soros-backed DA Descano in heated spat over soft-on-crime policy: ‘This is almost laughable’
-
Health10 minutes agoExperimental obesity drug outperforms traditional weight-loss treatments in early research
-
Sports16 minutes agoLeBron James may be target of apparently leaked Drake song featuring ‘switching teams’ lyric
-
Technology22 minutes agoFox News AI Newsletter: Graduation speaker praises AI, gets instantly booed
-
Business28 minutes ago
LinkedIn, Cisco and Amazon are the latest tech companies laying off more workers
-
Entertainment34 minutes agoBTS, Madonna and Shakira to perform at World Cup final halftime show
-
Lifestyle40 minutes ago‘Harry Potter’ soars under the Cosm spell with fantastical, theme-park-like effects
-
Politics46 minutes agoNewsom offers early peek at rosy budget projections